Jun 26, 2025 02:12AM UBS Downgrades CureVac (CVAC) to Neutral

Jun 24, 2025 04:40PM CureVac N.V. (CVAC) announces AGM results

Jun 24, 2025 04:35PM CureVac Announces Voting Results of General Meeting

Jun 13, 2025 04:17AM Jefferies Downgrades CureVac (CVAC) to Hold

Jun 12, 2025 06:45AM BioNTech (BNTX) to Acquire CureVac (CVAC) in Public Exchange Offer

May 28, 2025 04:07AM Citizens JMP Reiterates Market Outperform Rating on CureVac (CVAC)

May 20, 2025 07:15AM CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

May 15, 2025 04:45PM CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

Apr 10, 2025 07:30AM CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Apr 8, 2025 07:25AM CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

Apr 7, 2025 07:17AM CureVac N.V. (CVAC) Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy

Apr 7, 2025 07:15AM CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Mar 27, 2025 04:33PM CureVac N.V. (CVAC) Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

Mar 27, 2025 04:30PM CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

Mar 27, 2025 04:22PM CureVac N.V. (CVAC) Gets Positive Validity Decision In Suit Vs BioNTech (BNTX)

Feb 18, 2025 07:15AM CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators

Feb 5, 2025 12:41PM Dairy Cattle Test Positive for Bird Flu Strain Not Previously Seen in Cows, U.S. Department of Agriculture - Reuters

Jan 7, 2025 01:18PM CureVac N.V. (CVAC) call put ratio 17 calls to 1 put with a focus on January 5 calls as share price up 4.9%

Nov 15, 2024 10:53AM CureVac N.V. (CVAC) call put ratio 1 call to 3.8 puts with focus on January 2.5 puts

Nov 12, 2024 07:20AM CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

Nov 7, 2024 07:30AM CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

Nov 4, 2024 07:23AM CureVac N.V. (CVAC) Appoints Axel Sven Malkomes as CFO

Nov 4, 2024 07:20AM CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

Nov 4, 2024 07:15AM CureVac to Present at the 12th International mRNA Health Conference

Oct 28, 2024 08:10AM CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Sep 13, 2024 08:18AM CureVac's (CVAC) CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO

Sep 13, 2024 08:15AM CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Sep 12, 2024 07:17AM CureVac (CVAC) Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

Sep 12, 2024 07:15AM CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

Sep 9, 2024 07:15AM CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Aug 15, 2024 07:30AM CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

Aug 15, 2024 07:26AM CureVac N.V. (CVAC) Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

Aug 15, 2024 07:20AM CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

Aug 15, 2024 07:17AM CureVac (CVAC) Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

Aug 15, 2024 07:15AM CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

Jul 11, 2024 07:17AM CureVac N.V. (CVAC) Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

Jul 11, 2024 07:15AM CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

Jul 3, 2024 02:40AM GSK and CureVac to Restructure Collaboration into New Licensing Agreement

Jul 3, 2024 02:40AM CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

Jun 24, 2024 04:20PM CureVac Announces Voting Results of General Meeting